1)Mahlen SD:Serratia infections;From military experiments to current practice. Clin Microbiol Rev 24:755-791, 2011
2)Wilson AP, et al:Prevention and control of multi-drug-resistant Gram-negative bacteria;Recommendations from a Joint Working Party. J Hosp Infect 92 Suppl 1:S1-44, 2016
into healthcare settings;Guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control 6:113, 2017
4)日本環境感染学会多剤耐性菌感染制御委員会:多剤耐性グラム陰性菌感染制御のためのポジションペーパー,第2版.日環境感染会誌32(Suppl III):S1-26, 2017
infections. Clin Infect Dis 5:ciab1013, 2021
Clin Microbiol Infect 10:84-85, 2004
species. Antibiotics(Basel)9:254, 2020
producing AmpC beta-lactamase;Implications for antibiotic use. Antimicrob Agents Chemother 52:995-1000, 2008
genus. Antimicrob Agents Chemother 45:2287-2298, 2001
with difficult-to-treat resistance(DTR-P. aeruginosa). Clin Infect Dis 72:e169-e183, 2021
;Results from the INCREMENT cohort. Clin Infect Dis 65:1615-1623, 2017
comparing with carbapenems. BMC Infect Dis 16:427, 2016
infections. Antimicrob Agents Chemother 61:e02097-16, 2017